Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider
Nykode Therapeutics ASA (NYKD) · publisert 29. februar 2024 kl. 16:27 · vis på NewsWeb
Transaksjoner
| Person | Rolle | Type | Volum | Pris | Dato | ISIN | Handelsplass |
|---|---|---|---|---|---|---|---|
| Michael Engsig | – | Kjøp | 6 000 | 16,71 NOK | 29. februar 2024 | NO0010714785 | XOSL - Oslo Stock Exchange |
Vedlegg
- Attachment 240229.pdf (application/pdf, originaldokument)
Meldingstekst
Oslo, Norway, February 29, 2024 - Primary insider Michael Engsig, Chief Executive Officer of Nykode Therapeutics ASA, has today acquired 6,000 shares in Nykode Therapeutics ASA at a price of NOK 16.71 per share. Following the transaction, Michael Engsig holds 15,850 shares in Nykode Therapeutics ASA.
Please see further details in the attached document.